Drug intelligence / Profile preview

clomiphene + paroxetine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A drug combination consisting of clomiphene, a selective estrogen receptor modulator (SERM) used to treat infertility in women, and paroxetine, a selective serotonin reuptake inhibitor (SSRI) that functions as a strong CYP2D6 inhibitor. This combination has been studied to understand drug-drug-gene interactions, as clomiphene is primarily metabolized via CYP2D6 and CYP3A4 enzymes, and paroxetine can inhibit CYP2D6 activity, potentially affecting clomiphene metabolism and exposure.

Targets

SERT (Sodium-dependent serotonin transporter)ER (Estrogen receptor)CYP2D6 (Cytochrome P450 2D6)

Beyond the preview

Go deeper on clomiphene + paroxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clomiphene + paroxetine.

Explore the full profile